Unknown

Dataset Information

0

Ticagrelor Enhances Release of Anti-Hypoxic Cardiac Progenitor Cell-Derived Exosomes Through Increasing Cell Proliferation In Vitro.


ABSTRACT: Despite the widespread clinical use of cardioprotection by long-term direct antagonism of P2Y12 receptor, underlying mechanisms are unclear. Here, we identify how release of pro-survival exosomes from human cardiac-derived mesenchymal progenitor cells (hCPCs) is regulated by clinically relevant dose of ticagrelor (1??M), an oral selective and reversible non-thienopyridine P2Y12 inhibitor. Ticagrelor-induced enhancement of exosome levels is related to increased mitotic activity of hCPCs. We show a drug-response threshold above which the effects on hCPCs are lost due to higher dose of ticagrelor and larger adenosine levels. While it is known that pan-Aurora kinase inhibitor halts cell proliferation through dephosphorylation of histone H3 residue Ser10, we demonstrate that it also prevents ticagrelor-induced effects on release of cardiac progenitor cell-derived exosomes delivering anti-apoptotic HSP70. Indeed, sustained pre-treatment of cardiomyocytes with exosomes released from explant-derived hCPCs exposed to low-dose ticagrelor attenuated hypoxia-induced apoptosis through acute phosphorylation of ERK42/44. Our data indicate that ticagrelor can be leveraged to modulate release of anti-hypoxic exosomes from resident hCPCs.

SUBMITTER: Casieri V 

PROVIDER: S-EPMC7016113 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Ticagrelor Enhances Release of Anti-Hypoxic Cardiac Progenitor Cell-Derived Exosomes Through Increasing Cell Proliferation In Vitro.

Casieri Valentina V   Matteucci Marco M   Pasanisi Emilio M EM   Papa Angela A   Barile Lucio L   Fritsche-Danielson Regina R   Lionetti Vincenzo V  

Scientific reports 20200212 1


Despite the widespread clinical use of cardioprotection by long-term direct antagonism of P2Y12 receptor, underlying mechanisms are unclear. Here, we identify how release of pro-survival exosomes from human cardiac-derived mesenchymal progenitor cells (hCPCs) is regulated by clinically relevant dose of ticagrelor (1 μM), an oral selective and reversible non-thienopyridine P2Y<sub>12</sub> inhibitor. Ticagrelor-induced enhancement of exosome levels is related to increased mitotic activity of hCPC  ...[more]

Similar Datasets

| S-EPMC2756190 | biostudies-literature
| S-EPMC4509862 | biostudies-literature
| S-EPMC4258122 | biostudies-literature
| S-EPMC3979910 | biostudies-literature
| S-EPMC3488121 | biostudies-other
| S-EPMC3595054 | biostudies-literature
| S-EPMC3351910 | biostudies-literature
| S-EPMC8762953 | biostudies-literature
| S-EPMC9482506 | biostudies-literature
| S-EPMC5143405 | biostudies-literature